PharmaShots Interview: Takeda’s Chris Arendt Shares Insight on the Data of Alunbrig Presented at ESMO 2021

In an interview with PharmaShots, Chris Arendt, Head of the Oncology Therapeutic Area Unit at Takeda shared his views on the new data of Alunbrig in the P-III ALTA-1L study for the Treatment of ALK+ mNSCLC Shots: The P-III ALTA-1L study evaluates Alunbrig vs Crizotinib in patients with ALK+ mNSCLC who have not received prior treatment with an ALK inhibitor The results showed…

BySenior EditorNovember 22, 2021

VIEWPOINTS

PharmaShots Interview: Takeda Salom Juethner Shares Insights on the Data Publication to Support the Sustained Safety and Efficacy of Takhzyro

In an interview with PharmaShots, Salomé Juethner, Senior Medical Director, Rare Diseases at Takeda shared her views on the P-III HELP study of Takhzyro for the prevention of hereditary angioedema attacks in the Journal Allergy Shots: The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged =12yrs. with HAE attacks for ~2.5yrs.…

BySenior EditorOctober 6, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B,…

BySenior EditorSeptember 30, 2021

TOP 20

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020- the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy Our team at PharmaShots has compiled a list of top 20 oncology companies based on…

ByPrince GiriSeptember 9, 2021

VIEWPOINTS

PharmaShots Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2020

In an interview with PharmaShots, Nirav Desai, Global Clinical Development Lead at Takeda shared his views on TAK-721 data presented at ACG 2020 and its implications for patients and HCPs. The presentation includes post hoc analyses from a 12-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial that investigated the safety and efficacy of BOS in patients with EoE 11 to 55 years…

BySenior EditorMarch 29, 2021

INSIGHTS+

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available…

BySenior EditorMarch 11, 2021

VIEWPOINTS

PharmaShots Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation

In a recent interview with PharmaShots, Andrea Stancati, Vice President, Head GI Global Medical Franchise shares his insights and highlights of Entyvio (vedolizumab) Shots: The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD, following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE 2 (CD)…

BySenior EditorOctober 23, 2020

TOP 20

Top 20 Oncology Companies by Total Products of 2019

To remain successful in the oncology market- change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However- despite robust levels of pipeline activity- oncology remains a challenging area for research…

ByPrince GiriSeptember 24, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – February 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named 'SARS-CoV-2'(severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named 'Coronavirus Disease 2019'(COVID-19). The outbreak of the respiratory disease was first detected in Wuhan…

BySenior EditorFebruary 28, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – March 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019. PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorJanuary 31, 2020

PharmaShots Interview: Takeda’s Chris Arendt Shares Insight on the Data of Alunbrig Presented at ESMO 2021

PharmaShots Interview: Takeda Salom Juethner Shares Insights on the Data Publication to Support the Sustained Safety and Efficacy of Takhzyro

PharmaShots’ Key Highlights of Third Quarter 2021

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

PharmaShots Interview: Takeda’s Nirav Desai Shares Insight on Data of TAK-721 Presented at ACG 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

PharmaShots Interview: Takeda’s Andrea Stancati Shares Insights on Entyvio (vedolizumab) SC Formulation

Top 20 Oncology Companies by Total Products of 2019

Insights+: COVID-19 Healthcare News Monthly Updates – February 2020

Insights+: COVID-19 Healthcare News Monthly Updates – March 2020

Contact US

FOLLOW US